Life Biosciences Receives FDA Clearance for First-Ever Cellular Rejuvenation Therapy Using Epigenetic Reprogramming
核心洞察
Life Biosciences (搜索) has received FDA clearance for its IND application for ER-100, marking the first cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials.
The Phase 1 study will evaluate ER-100's safety and potential to improve vision in patients with open-angle glaucoma (搜索) and non-arteritic anterior ischemic optic neuropathy (搜索).
ER-100 utilizes three Yamanaka factors (OCT-4 (搜索), SOX-2 (搜索), and KLF-4 (搜索)) to restore aged or injured retinal cells to a younger state through intravitreal injection.
Life Biosciences (搜索) has achieved a groundbreaking regulatory milestone with FDA clearance of its Investigational New Drug (IND) application for ER-100, becoming the first cellular rejuvenation therapy using epigenetic reprogramming to receive authorization for human clinical trials. The Boston-based biotechnology company announced the clearance on January 28, 2026, enabling initiation of a Phase 1 clinical program targeting optic neuropathies (搜索).
Revolutionary Approach to Cellular Rejuvenation
ER-100 represents a novel therapeutic approach derived from Life Biosciences (搜索)' Partial Epigenetic Reprogramming (PER) platform. The therapy aims to restore aged or injured cells to a younger state by modifying the epigenome—biochemical markers that regulate gene expression without altering the underlying DNA sequence. The company's approach enables controlled expression of three of the four Yamanaka factors: the transcription factors OCT-4 (搜索), SOX-2 (搜索), and KLF-4 (搜索) (OSK).
"This important milestone in reaching the clinic is the result of years of research, optimization, and comprehensive nonhuman primate studies demonstrating controlled OSK expression, restoration of methylation patterns, and improved visual function, all of which has culminated in this IND clearance," said Sharon Rosenzweig-Lipson, Ph.D., Chief Scientific Officer at Life Biosciences (搜索).
Phase 1 Clinical Trial Design
The first-in-human study (NCT07290244) will enroll patients with two distinct optic neuropathies (搜索): open-angle glaucoma (搜索) (OAG) and non-arteritic anterior ischemic optic neuropathy (搜索) (NAION). The trial will assess ER-100's safety, tolerability, immune responses, and impact on multiple visual assessments through intravitreal injection—direct administration into the eye.
Preclinical studies in multiple animal models have demonstrated both safety and efficacy of the local injection approach, providing the foundation for human testing.
Addressing Critical Unmet Medical Needs
Optic neuropathies (搜索) represent a group of disorders characterized by irreversible death of retinal ganglion cells (搜索) (RGCs), the primary neurons connecting the eye to the brain. The inability of RGCs to naturally regenerate results in permanent vision impairment, creating substantial therapeutic challenges.
Open-angle glaucoma (搜索) stands as a chronic neurodegenerative disease and leading cause of blindness. While often associated with elevated intraocular pressure, RGC damage frequently continues despite treatment, and some patients develop OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (搜索), often termed "stroke of the eye," represents the most common acute optic neuropathy in adults over fifty, involving sudden, painless vision loss due to insufficient blood flow.
Currently, no approved treatments exist for NAION, while existing glaucoma therapies fail to address the underlying neuronal degeneration. The prevalence and incidence of both diseases rise with age, creating a growing global burden and highlighting the significant unmet medical need for disease-modifying therapies that can directly protect or regenerate RGCs.
Platform Technology with Broader Implications
Life Biosciences (搜索)' PER platform targets what the company describes as a root cause of aging at the epigenetic level, potentially offering applications across a wide range of age-related diseases. The company is strategically expanding its therapeutic pipeline beyond ER-100 to address additional age-related conditions, underscoring the platform's versatility and transformative potential.
The Phase 1 clinical trial for ER-100 is scheduled to initiate in the first quarter of 2026, representing a significant step forward in translating cellular rejuvenation research into potential therapeutic interventions for patients facing debilitating age-related diseases.